Mostrar el registro sencillo del ítem

dc.contributor.authorPaz-Ibarra, Jose
dc.contributor.authorLu-Antara, Jose
dc.contributor.authorUscamayta, Brenda-Erendida
dc.contributor.authorMartinez-Auris, Jhancy
dc.contributor.authorValencia-Rivera, Miriam
dc.contributor.authorSáenz-Bustamante, Sofía
dc.contributor.authorDelgado-Rojas, Marialejandra
dc.contributor.authorSalcedo-Vasquez, Julia
dc.contributor.authorConcepción-Zavaleta, Marcio
dc.date.accessioned2023-09-11T21:24:49Z
dc.date.available2023-09-11T21:24:49Z
dc.date.issued2023-04
dc.identifier.urihttps://hdl.handle.net/20.500.13053/9303
dc.description.abstract“Doege–Potter syndrome (DPS) is a paraneoplastic syndrome characterized by nonislet cell tumor hypoglycemia due to a solitary fibrous tumor, which produces insulin-like growth factor II. In this report, we present the case of a 67-year-old male with recurrent and refractory hypoglycemia due to DPS successfully treated with imatinib. He initially presented with neuroglycopenic symptoms and dyspnea secondary to a giant tumor in the left hemithorax, which was totally resected. During follow-up, 7 years later, he presented with thoracoabdominal tumor recurrence associated with severe hypoglycemia and underwent subtotal tumor resection, with a subsequent improvement of symptoms. The following year, he had a recurrence of his intra-abdominal tumor, which was unresectable, associated with severe hypoglycemia refractory to dextrose infusion and corticosteroids, thus receiving imatinib with a favorable response. The clinical presentation, diagnostic approach, progression of the disease, and response to treatment with imatinib in the management of a patient with large, recurrent, and unresectable mesenchymal tumors with insulin-like growth factor-2 secretion causing hypoglycemia highlight the importance of this case report“es_PE
dc.formatapplication/pdfes_PE
dc.language.isoenges_PE
dc.publisherBioScientifica Ltd.es_PE
dc.rightsinfo:eu-repo/semantics/openAccesses_PE
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/es_PE
dc.subjectDoege–Potter, Solitary fibrous tumores_PE
dc.titleImatinib use in the management of a patient with Doege–Potter syndromees_PE
dc.typeinfo:eu-repo/semantics/articlees_PE
dc.identifier.doi10.1530/EDM-22-0360
dc.type.versioninfo:eu-repo/semantics/publishedVersiones_PE
dc.publisher.countryGBRes_PE
dc.subject.ocde3.03.00 -- Ciencias de la saludes_PE


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(es)

Mostrar el registro sencillo del ítem

info:eu-repo/semantics/openAccess
Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/openAccess